As a Free StocksGuide user, you can view scores for all 7,021 stocks worldwide.
16 Analysts have issued a Apogee Therapeutics forecast:
16 Analysts have issued a Apogee Therapeutics forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -270 -270 |
88%
88%
|
|
| EBIT (Operating Income) EBIT | -271 -271 |
88%
88%
|
|
| Net Profit | -238 -238 |
101%
101%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in February 2022 and is headquartered in Waltham, MA.
| Head office | United States |
| CEO | Michael Henderson |
| Employees | 196 |
| Founded | 2022 |
| Website | apogeetherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


